Gsk and xenoport receive FDA approval for horizant for postherpetic neuralgia

XenoPort, 06/08/2012

GlaxoSmithKline plc (GSK) and XenoPort, Inc. announced that the United States (US) Food and Drug Administration (FDA) has approved Horizant (gabapentin enacarbil) Extended–Release Tablets for the management of postherpetic neuralgia (PHN) in adults.

Print Article Summary